Chimeric Antigen Receptor (CAR) Cell Therapy Related Cardiovascular Outcomes

Study Summary

This will be a cohort study of all patients receiving Cluster of Differentiation 19 (CD19)-specific CAR T cell therapy for relapsed/refractory B cell haematological malignancies. Patients will receive cardiac assessment and have serum cardiac biomarkers, ECG, transthoracic echocardiogram and cardiac magnetic resonance imaging performed at baseline prior to CAR T cell therapy, 7 days post CAR T cell infusion, and 3 months post CAR T cell infusion. Abnormalities in these cardiac investigations will be used to demonstrate cardiac injury and identify which patients are most at risk of developing cardiac injury related to CAR T cell therapy.

Interventions

No interventions listed.

Study Locations

Facility	City	State	Country
University College London Hospitals	London		United Kingdom

Official Trial Information

View on ClinicalTrials.gov